HC Biologics’ Post

What is the INPDR Gateway? | Toni Mathieson | International Niemann-Pick Disease Registry The INPDR Gateway platform offers controlled access to registry information and enables collaboration with external commercial organisations, including biopharmaceutical companies. Such partnerships support the clinical research needs of our stakeholders and provide organisations with real-world evidence that can inform the development of therapies and treatments and drive meaningful change for patients. As the largest active database on the diagnosis, management, and progression of Niemann-Pick diseases, the INPDR is committed to improving health outcomes for Niemann-Pick patients through data sharing and analytics, accurately reporting patient experience, in order to improve that experience. In this short video, INPDR Board Trustee Toni Mathieson gives more insight into the role of INPDR Gateway. #INPDR #Gateway #Database #NiemannPick

Summed up perfectly by Toni, the INPDR is creating a comprehensive resource that supports research, improves clinical management, and empowers patients and families of Niemann-Pick Disease worldwide. Let’s continue to support and contribute to this vital initiative. Together, we can make a difference! 💪 #NiemannPickDisease #INPDR #Gateway #Database #PatientCare #MedicalResearch

✊ PTC Therapeutics Partners with Novartis 🤝 PTC Therapeutics, Inc. teams up with Novartis to accelerate advancements in innovative treatments, strengthening global healthcare solutions! Know complete story: https://lnkd.in/dqPUeajv #PharmaNews #Partnerships #HealthcareInnovation #PharmaceuticalIndustry #GlobalHealth

The results are in!   Last week, AtomVie Global Radiopharma (AtomVie) put out a poll to our community to get a better understanding of where our audience thinks the biggest challenges of radiopharmaceutical development and manufacturing currently lies, and we wanted to share that so far "Commercial Production Scaling" was voted as the biggest challenge.   At AtomVie, we are committed to supporting our clients and partners in the development and manufacturing of their assets through all stages from clinical to commercial with our dedicated teams. Together, we aim to transform patients' lives with high-quality radiopharmaceuticals. Explore the range of services in the graphic below or visit our website - https://lnkd.in/eRfgP6FK. If you have any questions, please feel free to reach out to us at info@atomvie.com. Also, be sure to check out our new facility page, which highlights our upcoming manufacturing facility designed to support our partners' clinical and commercial manufacturing needs, bringing cutting-edge solutions to patients worldwide.   Thank you to everyone who participated in our poll, or engaged with the post. If there are any specific topics you’d like us to explore, comment your ideas below. Stay tuned for more updates on our LinkedIn page, as we continue to innovate and collaborate in the exciting world of radiopharmaceuticals!   #AtomVieGlobalRadiopharma #RadiopharmaceuticalDevelopment #IndustryChallenges #CommercialManufacturing #TransformingLives #Results 

Imagine a world where life-changing treatments are within reach for everyone. Biosimilars are making this vision a reality—opening doors to innovative, affordable treatments that bring renewed hope to families and help reduce healthcare costs globally. As we celebrate #GlobalBiosimilarsWeek, understanding the role of biosimilars is more important than ever. Curious about why biosimilars are essential?  The New Handbook on Biosimilars by Karger, supported by Biocon Biologics, offers a comprehensive guide to the science and regulatory pathways behind these transformative medicines, crafted specifically for healthcare professionals. Visit the Biocon Biologics website to learn more about the power of biosimilars. Let’s support a future where better health is accessible to everyone, everywhere. Read More & Download : https://bit.ly/4hHXjiR #GlobalBiosimilarsWeek #AdvancingAccess #HealthcareInnovation #Biosimilars #HealthcareForAll #AffordableMedicine #BioconBiologics Shreehas Tambe Mandar Ghatnekar Kedar Upadhye Rhonda Duffy Naveen Narayanan Matt Erick Anuj Goel Susheel Umesh Seema Shah Ahuja Stephanie Wasco Arlene Wolny Uwe Gudat Ankur Bhatnagar Kathleen Blanchard Akhilesh Nand Stephen Fecho, Jr Dwight Hanshew Ganesh Reddy D Dave Gibson Jozef Belcik Paul Harmon RPN, MBA, MSc. Wakim Andre Rinat Livne Marcelo Holanda Souhail Tebib Jay (Jihad) Bou Daher

Stifel is pleased to share the latest Biopharma Market Report. This publication features notable industry news, a deep dive into the Trump Administration’s recent healthcare appointments, as well as an analysis of the biotech sector’s balance sheet condition. Click below to learn more: #biotech #biopharma #Trump #healthcare #balancesheet

Exciting insights from Pharma Manufacturing on how bispecific antibodies are revolutionizing treatment options across various diseases. Bispecific antibodies, with their ability to target multiple disease pathways simultaneously, represent a significant leap forward in precision medicine. They offer new hope for conditions where traditional therapies fall short, promising better outcomes and fewer side effects. These innovations are reshaping how we approach healthcare. As we embrace these advancements, integrating robust #WorkflowAutomation becomes significant. Streamlining processes ensures these groundbreaking therapies reach those who need them efficiently and safely. #Biopharma #PrecisionMedicine #HealthcareAdvancements #MedTech

Groundbreaking Advances Shared at the Transdermal Conference! 🥼 Earlier today, Brian Pfister, VP at Gylden Pharma, highlighted remarkable progress in next-gen vaccine delivery using hollow microneedles. Key takeaways included stable COVID-19 vaccine coating on microneedle patches and encouraging Phase I results from the naNO-Dengue trial. 🌐💉 With a proprietary microneedle platform leading the way, we’re witnessing a new era in vaccine technology 🤖 #SAETransdermal #TransdermalDelivery #MicroneedleTechnology #PharmaInnovation #DrugDelivery #HealthcareInnovation #TransdermalPatch #MedicalAdvancements #PharmaConference #MicroneedleSolutions #SAEMGPharma

We are pleased to share a new #PressRelease: Last Patient Last Visit in #SHINE Clinical Trial! This important milestone marks a significant success, surpassing the planned enrollment of 288 with 318 participants. SiPore21® has the potential to be the first medically approved treatment specifically targeting #prediabetes, offering a promising #nonpharmaceutical alternative to #GLP1 treatments. With top-line results anticipated in Q1 2025, we are poised for CE marking and rapid #marketaccess in the U.S. Sana Alajmovic, Co-Founder & CEO, stated, “Our goal with SiPore21® is to provide an accessible, non-pharmaceutical solution for #bloodsugarcontrol, empowering millions worldwide to manage their #metabolichealth proactively.” As the demand for effective metabolic health solutions continues to grow, SiPore21® represents a significant opportunity for #partnerships in this fast-growing sector. 🔗 Read more: https://lnkd.in/dZw9S2vV

We’re raising awareness for #biosimilars and the important role they play in expanding access to care in healthcare systems around the globe. At Teva, we believe that unlocking value in biologics is essential, and that value creation is the key to broadening patient access and lowering system costs around the globe. Together we can make a difference in the lives of patients through policies that support #biosimilar adoption and education. Discover the magic of biosimilars here. https://lnkd.in/dBvZfHyc #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm